Regeneron stock falls on Eylea sales miss

Investing.com — Shares of Regeneron (NASDAQ:) Pharmaceuticals (NASDAQ:REGN) fell 4% in premarket trading after the company reported lower-than-expected sales for a higher dose of its flagship eye drug, Eylea.

The drug’s sales in the fourth quarter of 2024 were significantly below analyst expectations, contributing to the stock’s decline.

Eylea HD, the higher dose of Regeneron’s widely used eye treatment, generated US net product sales of $305 million in the fourth quarter, a stark contrast to the $457 million that had been estimated.

Chris Schott (ETR:) of JPMorgan, maintaining an overweight rating on Regeneron, commented on the sales figures, stating, “Eylea HD sales in 4Q were well below consensus.”

He further noted that “it appears Eylea HD sales have effectively plateaued,” indicating a possible stagnation in the product’s revenue stream.

Regeneron’s Eylea has been a key product for the company, and its performance is closely watched by investors. The lower sales figures for the higher dose version could reflect challenges in market penetration or competition from other treatments.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.